Literature DB >> 9682348

Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).

V Udhayakumar1, A Saekhou, S Fang, D Jue, R M Wohlhueter, A A Lal.   

Abstract

In this study we characterized the immunogenic properties of three different multispecies multiple antigen constructs (MACs) carrying the circumsporozoite protein (CSP) repeats of human malaria parasites, Plasmodium falciparum and P. vivax. We synthesized tetrameric MACs containing the antigenic repeats from the CSP of P. vivax-like parasite in two arms and CSP repeat sequences of either P. vivax type-1 (vivax-like/vivax type-1 MAC), P. vivax type-2 (vivax-like/vivax type-2 MAC), or P. falciparum (vivax-like/falciparum MAC) in the other two arms. Mice of four different genetic backgrounds (H-2a, H-2b, H-2d, and H-2k) were immunized with these MACs in Freund's adjuvant. All three MAC preparations were found to elicit antibodies to P. vivax-like CSP repeats in B10.BR, B10.A, and C57BL/6 mice. On the other hand, in B10.D2 mice only vivax-like/vivax type-1 MAC, but not the other two MACs induced antibodies to the P. vivax-like CSP repeats. In mice immunized with vivax-like/vivax type-1 MAC, antibodies to P. vivax type-1 CS repeat peptides were induced in B10.BR, B10.A, and C57BL/6 mice, but not in B10.D2 mice. Antibody responses to P. vivax type-2 repeats were not induced in any of the four strains of mice that were immunized with vivax-like/vivax type-2 MAC. While B10.BR, B10.A, and C57BL/6 mice produced antibodies to NANP repeats of P. falciparum CSP following immunization with vivax-like/falciparum MAC, B10.D2 mice failed to elicit antibodies to this repeat. All the sera that showed positive reactivity to peptides in enzyme-linked immunosorbent assay were found to react with sporozoites by IFA. In conclusion, these results showed that naturally immunogenic epitopes from different species of malaria parasites can be incorporated in a single vaccine construct to induce immune responses against multiple epitopes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682348     DOI: 10.1016/s0264-410x(97)00290-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.

Authors:  James J Moon; Heikyung Suh; Adrienne V Li; Christian F Ockenhouse; Anjali Yadava; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-12       Impact factor: 11.205

2.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

3.  The use of a chimeric antigen for Plasmodium falciparum and P. vivax seroprevalence estimates from community surveys in Ethiopia and Costa Rica.

Authors:  Jessica N McCaffery; Balwan Singh; Douglas Nace; Ashenafi Assefa; Jimee Hwang; Mateusz Plucinski; Nidia Calvo; Alberto Moreno; Venkatachalam Udhayakumar; Eric Rogier
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

4.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

5.  Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.

Authors:  James J Moon; Heikyung Suh; Mark E Polhemus; Christian F Ockenhouse; Anjali Yadava; Darrell J Irvine
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

6.  Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.

Authors:  Yang Cheng; Daisuke Ito; Jetsumon Sattabongkot; Chae Seung Lim; Deok-Hoon Kong; Kwon-Soo Ha; Bo Wang; Takafumi Tsuboi; Eun-Taek Han
Journal:  Malar J       Date:  2013-09-14       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.